A Cure In Sight™ was founded to provide patient support services for Ocular Melanoma eye cancer patients. Ocular Melanoma (OM), also known as Uveal Melanoma, is the most common primary cancer of the eye in adults. Our patient population is unique in that our numbers are small with only an estimated 2,500 new diagnoses (US) per year. This alone has gained us “rare cancer status”.
The prognosis for those patients diagnosed with ocular melanoma can be dire. At this time, half of those diagnosed with OM will see their disease spread to other parts of the body. And, once metastasized, it is nearly always fatal. Currently there is no cure for metastatic ocular melanoma. There are, however, promising new treatments being prescribed, as well as new clinical trials and targeted therapies being proposed. These emerging treatment opportunities will only be made possible through research funding. Unfortunately, funding dollars are critically low. Grants for funding are rare and the competition is fierce. Therefore, we rely on private and corporate funding to fuel our programs and services.
A Cure in Sight (ACIS) helps provide services nationwide through building public awareness, educating OM patients and their caregivers, funding on-going eye cancer research, and by financially helping in-need OM patients find and pay for the treatments they need. However, funding is greatly needed for us to continue fulfilling our mission.
ACIS is uniquely positioned to serve the OM patient population. And, this is why our mission is so valuable to our community. Our actions have awarded us with an open door to many of the top ocular medical physicians and oncologists in the nation. We support each other and we are fighting everyday for a cure. If you are newly diagnosed, we welcome you and encourage you to tell your story. ACIS was founded by patients, run by patients and staffed completely by volunteers, their families, and their friends.